Tobira Says Secondary Endpoint In NASH Will Carry CVC Into Pivotal Study

The biotech argues that success in reducing fibrosis is more important than the failed primary endpoint measuring NAFLD activity score improvement – and also meets FDA's expectations – but the firm is taking a beating nonetheless.

Tobira Therapeutics Inc.'s CENTAUR trial may have failed on the primary endpoint, but the firm argues that the success on a key secondary endpoint of its Phase IIb study of cenicriviroc in NASH fits FDA's expressed standards for approval.

On July 25, Tobira announced that cenicriviroc (CVC), its dual CCR2/CCR5 inhibitor, missed the primary endpoint of improvement in the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from R&D

More from Pink Sheet